New tacrine-4-oxo-4H-chromene hybrids as multifunctional agents for the treatment of Alzheimer's disease, with cholinergic, antioxidant, and β-amyloid-reducing properties

Journal of Medicinal Chemistry

Volumn 55, Issue 3, 2012, Pages 1303-1317

  Fernández Bachiller, María Isabel ^a,b   Pérez, Concepción ^a   Monjas, Leticia ^a   Rademann, Jörg ^b,c   Rodríguez Franco, María Isabel ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^b LEIBNIZ INSTITUT FÜR MOLEKULARE PHARMAKOLOGIE   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 OXO N [10 [(1,2,3,4 TETRAHYDROACRIDIN 9 YL)AMINO]DECYL] 4H CHROMENE 2 CARBOXAMIDE; 4 OXO N [12 [(1,2,3,4 TETRAHYDROACRIDIN 9 YL)AMINO]DECYL] 4H CHROMENE 2 CARBOXAMIDE; 4 OXO N [7 [(1,2,3,4 TETRAHYDROACRIDIN 9 YL)AMINO]HEPTYL] 4H CHROMENE 2 CARBOXAMIDE; 4 OXO N [8 [(1,2,3,4 TETRAHYDROACRIDIN 9 YL)AMINO]OCTYL] 4H CHROMENE 2 CARBOXAMIDE; 4 OXO N [9 [(1,2,3,4 TETRAHYDROACRIDIN 9 YL)AMINO]NONYL] 4H CHROMENE 2 CARBOXAMIDE; 5,7 DIMETHOXY 4 OXO N [10 [(1,2,3,4 TETRAHYDROACRIDIN 9 YL)AMINO]DECYL] 4H CHROMENE 2 CARBOXAMIDE; 6 CHLOROTACRINE; 6 HYDROXY 4 OXO N [10 [(1,2,3,4 TETRAHYDROACRIDIN 9 YL)AMINO]DECYL] 4 H CHROMENE 2 CARBOXAMIDE; 6 HYDROXY 4 OXO N [10 [(1,2,3,4 TETRAHYDROACRIDIN 9 YL)AMINO]DECYL] 4H CHROMENE 2 CARBOXAMIDE; 6,7 DIHYDROXY 4 OXO N [10 [(1,2,3,4 TETRAHYDROACRIDIN 9 YL)AMINO]DECYL] 4H CHROMENE 2 CARBOXAMIDE; 6,7 DIMETHOXY 4 OXO N [10 [(1,2,3,4 TETRAHYDROACRIDIN 9 YL)AMINO]DECYL] 4H CHROMENE 2 CARBOXAMIDE; AMYLOID BETA PROTEIN; APIGENIN; BETA SECRETASE 1; CHOLINESTERASE; CHROMENE DERIVATIVE; FLAVONOID; N [10 [(6 CHLORO 1,2,3,4 TETRAHYDROACRIDIN 9 YL)AMINO]DECYL] 4 OXO 4H CHROMENE 2 CARBOXAMIDE; N [10 [(6 CHLORO 1,2,3,4 TETRAHYDROACRIDIN 9 YL)AMINO]DECYL] 5,7 DIMETHOXY 4 OXO 4H CHROMENE 2 CARBOXAMIDE; N [10 [(6 CHLORO 1,2,3,4 TETRAHYDROACRIDIN 9 YL)AMINO]DECYL] 6 HYDROXY 4 OXO 4H CHROMENE 2 CARBOXAMIDE; N [10 [(6 CHLORO 1,2,3,4 TETRAHYDROACRIDIN 9 YL)AMINO]DECYL] 6 METHOXY 4 OXO 4H CHROMENE 2 CARBOXAMIDE; N [10 [(6 CHLORO 1,2,3,4 TETRAHYDROACRIDIN 9 YL)AMINO]DECYL] 6,7 DIHYDROXY 4 OXO 4H CHROMENE 2 CARBOXAMIDE; N [10 [(6 CHLORO 1,2,3,4 TETRAHYDROACRIDIN 9 YL)AMINO]DECYL] 6,7 DIMETHOXY 4 OXO 4H CHROMENE 2 CARBOXAMIDE; N [10 [(6,8 DICHLORO 1,2,3,4 TETRAHYDROACRIDIN 9 YL)AMINO]DECYL] 4 OXO 4H CHROMENE 2 CARBOXAMIDE; N [10 [(6,8 DICHLORO 1,2,3,4 TETRAHYDROACRIDIN 9 YL)AMINO]DECYL] 6 HYDROXY 4 OXO 4H CHROMENE 2 CARBOXAMIDE; N [10 [(6,8 DICHLORO 1,2,3,4 TETRAHYDROACRIDIN 9 YL)AMINO]DECYL] 6 METHOXY 4 OXO 4H CHROMENE 2 CARBOXAMIDE; OXYGEN RADICAL; TACRINE 4 OXO 4H CHROMENE; TACRINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CHOLINERGIC ACTIVITY; CONTROLLED STUDY; DRUG DESIGN; DRUG PENETRATION; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTIOXIDANTS; ASPARTIC ACID ENDOPEPTIDASES; BENZOPYRANS; BLOOD-BRAIN BARRIER; BUTYRYLCHOLINESTERASE; CATALYTIC DOMAIN; CATTLE; CHOLINESTERASE INHIBITORS; CHROMONES; FREE RADICAL SCAVENGERS; HUMANS; MEMBRANES, ARTIFICIAL; PERMEABILITY; STRUCTURE-ACTIVITY RELATIONSHIP; TACRINE;

EID: 84856914519     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201460y     Document Type: Article

References (84)

1. Querfurth, H. W.; LaFerla, F. M. Alzheimer's disease N. Engl. J. Med. 2010, 362, 329-344
2. Holzgrabe, U.; Kapková, P.; Alptüzüun, V.; Scheiber, J.; Kugelmann, E. Targeting acetylcholinesterase to treat neurodegeneration Expert Opin. Ther. Targets 2007, 11, 161-179 (Pubitemid 46188812)
3. Castro, A.; Conde, S.; Rodríguez-Franco, M. I.; Martínez, A. Non-cholinergic pharmacotherapy approaches to the future treatment of Alzheimer's disease Mini Rev. Med. Chem. 2002, 2, 37-50
4. Smith, D. A. Treatment of Alzheimer's disease in the long-term-care setting Am. J. Health Syst. Pharm. 2009, 66, 899-907
5. Grossberg, G. T.; Pejović, V.; Miller, M. L.; Graham, S. M. Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease Dementia Geriatr. Cognit. Disord. 2009, 27, 164-172
6. Walsh, D. M.; Selkoe, D. J. A beta oligomers-a decade of discovery J. Neurochem. 2007, 101, 1172-1184
7. Conde, S. beta-Amyloid peptide as a target for treatment of Alzheimer's disease Expert Opin. Ther. Pat. 2002, 12, 503-512 (Pubitemid 34308867)
8. De Strooper, B.; Vassar, R.; Golde, T. The secretases: enzymes with therapeutic potential in Alzheimer's disease Nat. Rev. Neurol. 2010, 6, 99-107
9. Castro, A.; Martínez, A. Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors Curr. Pharm. Des. 2006, 12, 4377-4387 (Pubitemid 44718295)
10. Lannfelt, L.; Blennow, K.; Zetterberg, H.; Batsman, S.; Ames, D.; Harrison, J.; Masters, C. L.; Targum, S.; Bush, A. I.; Murdoch, R.; Wilson, J.; Ritchie, C. W.; PBT2-201-EURO study group Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial Lancet Neurol. 2008, 7, 779-786
11. Faux, N. G.; Ritchie, C. W.; Gunn, A.; Rembach, A.; Tsatsanis, A.; Bedo, J.; Harrison, J.; Lannfelt, L.; Blennow, K.; Zetterberg, H.; Ingelsson, M.; Masters, C. L.; Tanzi, R. E.; Cummings, J. L.; Herd, C. M.; Bush, A. I. PBT2 rapidly improves cognition in Alzheimer's disease: additional phase II analyses J. Alzheimers Dis. 2010, 20, 509-516
12. Evin, G.; Lessene, G.; Wilkins, S. BACE inhibitors as potential drugs for the treatment of Alzheimer's disease: focus on bioactivity Recent Pat. CNS Drug Discovery 2011, 6, 91-106
13. Inestrosa, N. C.; Dinamarca, M. C.; Alvarez, A. Amyloid-cholinesterase interactions. Implications for Alzheimer's disease FEBS J. 2008, 275, 625-632 (Pubitemid 351160969)
14. Rees, T.; Hammond, P. I.; Soreq, H.; Younkin, S.; Brimijoin, S. Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex Neurobiol. Aging 2003, 24, 777-787 (Pubitemid 37288853)
15. De Ferrari, G. V.; Canales, M. A.; Shin, I.; Weiner, L. M.; Silman, I.; Inestrosa, N. C. A structural motif of acetylcholinesterase that promotes amyloid β-peptide fibril formation Biochemistry 2001, 40, 10447-10457 (Pubitemid 32816655)
16. Cavalli, A.; Bolognesi, M. L.; Capsoni, S.; Andrisano, V.; Bartolini, M.; Margotti, E.; Cattaneo, A.; Recanatini, M.; Melchiorre, C. A small molecule targeting the multifactorial nature of Alzheimer's disease Angew. Chem., Int. Ed. 2007, 46, 3689-3692 (Pubitemid 46981250)
17. García-Palomero, E.; Muñoz, P.; Usan, P.; Garcia, P.; De Austria, C.; Valenzuela, R.; Rubio, L.; Medina, M.; Martínez, A. Potent β-amyloid modulators Neurodegener. Dis. 2008, 5, 153-156
18. Spuch, C.; Antequera, D.; Fernández-Bachiller, M. I.; Rodríguez-Franco, M. I.; Carro, E. A new tacrine-melatonin hybrid reduces amyloid burden and behavioral deficits in a mouse model of Alzheimer's disease Neurotox. Res. 2010, 17, 421-431
19. Perry, E. K.; Perry, R. H.; Blessed, G.; Tomlinson, B. E. Changes in brain cholinesterases in senile dementia of Alzheimer type Neuropathol. Appl. Neurobiol. 1978, 4, 273-277 (Pubitemid 9001675)
20. Lane, R. M.; Potkin, S. G.; Enz, A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia Int. J. Neuropsychopharmacol. 2006, 9, 101-124 (Pubitemid 43068340)
21. Greig, N.; Utsuki, T.; Ingram, D.; Wang, Y.; Pepeu, G.; Scali, C.; Yu, Q.; Mamczarz, J.; Holloway, H.; Giordano, T.; Chen, D.; Furukawa, K.; Sambamurti, K.; Brossi, A.; Lahiri, D. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 17213-17218 (Pubitemid 41692709)
22. Venneri, A.; Shanks, M. F.; Staff, R. T.; Pestell, S. J.; Forbes, K. E.; Gemmell, H. G.; Murray, A. D. Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease Neuroreport 2002, 13, 83-87 (Pubitemid 34102031)
23. Venneri, A.; McGeown, W. J.; Shanks, M. F. Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer's disease Neuroreport 2005, 16, 107-110 (Pubitemid 40250379)
24. Venneri, A.; Lane, R. Effects of cholinesterase inhibition on brain white matter volume in Alzheimer's disease Neuroreport 2009, 20, 285-288
25. Shanks, M.; Kivipelto, M.; Bullock, R.; Lane, R. Cholinesterase inhibition: is there evidence for disease-modifying effects? Curr. Med. Res.Opin. 2009, 25, 2439-2446
26. Gu, F.; Zhu, M.; Shi, J.; Hu, Y.; Zhao, Z. Enhanced oxidative stress is an early event during development of Alzheimer-like pathologies in presenilin conditional knock-out mice Neurosci. Lett. 2008, 440, 44-48
27. Moreira, P. I.; Santos, M. S.; Oliveira, C. R.; Shenk, J. C.; Nunomura, A.; Smith, M. A.; Zhu, X.; Perry, G. Alzheimer disease and the role of free radicals in the pathogenesis of the disease CNS Neurol. Disord. Drug Targets 2008, 7, 3-10 (Pubitemid 351516211)
28. Ansari, M. A.; Scheff, S. W. Oxidative stress in the progression of Alzheimer disease in the frontal cortex J. Neuropathol. Exp. Neurol. 2010, 69, 155-167
29. Reddy, V. P.; Zhu, X.; Perry, G.; Smith, M. A. Oxidative stress in diabetes and Alzheimer's disease J. Alzheimers Dis. 2009, 16, 763-774
30. Beking, K.; Vieira, A. Flavonoid intake and disability-adjusted life years due to Alzheimer's and related dementias: a population-based study involving twenty-three developed countries Public Health Nutr. 2010, 13, 1403-1409
31. Lee, H. P.; Casadesus, G.; Zhu, X.; Lee, H. G.; Perry, G.; Smith, M. A.; Gustaw-Rothenberg, K.; Lerner, A. All-trans retinoic acid as a novel therapeutic strategy for Alzheimer's disease Expert Rev. Neurother. 2009, 9, 1615-1621
32. Zhang, H. Y.; Yang, D. P.; Tang, G. Y. Multipotent antioxidants: from screening to design Drug Discovery Today 2006, 11, 749-754
33. Osseni, R. A.; Debbasch, C.; Christen, M.-O.; Rat, P.; Warnet, J.-M. Tacrine-induced reactive oxygen species in a human liver cell line: The role of anethole dithiolethione as a scavenger Toxicol. In Vitro 1999, 13, 683-688 (Pubitemid 29354196)
34. Dogterom, P.; Nagelkerke, J. F.; Mulder, G. J. Hepatotoxicity of tetrahydroaminoacridine in isolated rat hepatocytes: Effect of glutathione and vitamin E Biochem. Pharmacol. 1988, 37, 2311-2313
35. Tumiatti, V.; Minarini, A.; Bolognesi, M. L.; Milelli, A.; Rosini, M.; Melchiorre, C. Tacrine derivatives and Alzheimer's disease Curr. Med. Chem. 2010, 17, 1825-1838
36. Rosini, M.; Andrisano, V.; Bartolini, M.; Bolognesi, M. L.; Rehíla, P.; Minarini, A.; Tarozzi, A.; Melchiorre, C. Rational approach to discover multipotent anti-Alzheimer drugs J. Med. Chem. 2005, 48, 360-363 (Pubitemid 40139781)
37. Fernández-Bachiller, M. I.; Pérez, C.; Campillo, N. E.; Páez, J. A.; González-Muñoz, G. C.; Usán, P.; García-Palomero, E.; López, M. G.; Villarroya, M.; García, A. G.; Martínez, A.; Rodríguez-Franco, M. I. Tacrine-melatonin hybrids as multifunctional agents for Alzheimer's disease, with cholinergic, antioxidant, and neuroprotective properties ChemMedChem. 2009, 4, 828-841
38. Fernández-Bachiller, M. I.; Pérez, C.; González- Muñoz, G. C.; Conde, S.; López, M. G.; Villarroya, M.; García, A. G.; Rodríguez-Franco, M. I. Novel tacrine-8- hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimer's disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties J. Med. Chem. 2010, 53, 4927-4937
39. Fang, L.; Appenroth, D.; Decker, M.; Kiehntopf, M.; Roegler, C.; Deufel, T.; Fleck, C.; Peng, S.; Zhang, Y.; Lehmann, J. Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates J. Med. Chem. 2008, 51, 713-716 (Pubitemid 351304679)
40. Spencer, J. P. The impact of flavonoids on memory: physiological and molecular considerations Chem. Soc. Rev. 2009, 38, 1152-1161
41. Spencer, J. P. Beyond antioxidants: the cellular and molecular interactions of flavonoids and how these underpin their actions on the brain Proc. Nutr. Soc. 2010, 69, 244-260
42. Shimmyo, Y.; Kihara, T.; Akaike, A; Niidome, T.; Sugimoto, H. Flavonols and flavones as BACE-1 inhibitors: structure-activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features Biochim. Biophys. Acta 2008, 1780, 819-825
43. Shimmyo, Y.; Kihara, T.; Akaike, A.; Niidome, T.; Sugimoto, H. Multifunction of myricetin on A beta: neuroprotection via a conformational change of A beta and reduction of A beta via the interference of secretases J. Neurosci. Res. 2008, 86, 368-377 (Pubitemid 351196742)
44. Cavalli, A.; Bolognesi, M. L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed ligands to combat neurodegenerative diseases J. Med. Chem. 2008, 51, 347-372 (Pubitemid 351252260)
45. Bolognesi, M. L.; Cavalli, A.; Melchiorre, C. Memoquin: a multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer's disease Neurotherapeutics 2009, 6, 152-162
46. Rodríguez-Franco, M. I.; Fernández-Bachiller, M. I.; Pérez, C.; Castro, A.; Martínez, A. Design and synthesis of N-benzylpiperidine purine derivatives as new dual inhibitors of acetyl- and butyrylcholinesterase Bioorg. Med. Chem. 2005, 13, 6795-6802 (Pubitemid 41571225)
47. Rodríguez-Franco, M. I.; Dorronsoro, I.; Castro, A.; Martínez, A.; Badía, A.; Baños, J.-E. Synthesis and muscarinic activities of o -[(benzyl- or benzoyl-pyrazolyl)propynyl]-oximes of N -methylpiperidinone, 3-tropinone, and 3-quinuclidinone Bioorg. Med. Chem. 2003, 11, 2263-2268
48. Rodríguez-Franco, M. I.; Dorronsoro, I.; Martínez, A. O -Pyrazolylpropynyl-Hydroxylamines as Versatile Intermediates in the Synthesis of Compounds of Pharmacological Interest Synthesis 2001, 1711-1715 (Pubitemid 32831671)
49. Rodríguez-Franco, M. I.; Dorronsoro, I.; Martínez, A.; Pérez, C.; Badía, A.; Baños, J.-E. Synthesis of new N -(4-Pyridyl)-1-aminopyrazoles and their muscarinic and adrenergic properties Arch. Pharm.-Pharm. Med. Chem. 2000, 333, 118-122
50. Maroto, M.; de Diego, A. M.; Albiñana, E.; Fernández- Morales, J. C.; Caricati-Neto, A.; Jurkiewicz, A.; Yáñez, M.; Rodríguez-Franco, M. I.; Conde, S.; Arce, M. P.; Hernández-Guijo, J. M.; García, A. G. Multi-target novel neuroprotective compound ITH33/IQM9.21 inhibits calcium entry, calcium signals and exocytosis Cell Calcium 2011, 50, 359-369
51. González-Muñoz, G. C.; Arce, M. P.; López, B.; Pérez, C.; Romero, A.; del Barrio, L.; Martín-de-Saavedra, M. D.; Egea, J.; León, R.; Villarroya, M.; López, M. G.; García, A. G.; Conde, S.; Rodríguez-Franco, M. I. N -Acylaminophenothiazines: neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease Eur. J. Med. Chem. 2011, 46, 2224-2235
52. González-Muñoz, G. C.; Arce, M. P.; Pérez, C.; Villarroya, M.; López, M. G.; García, A. G.; Conde, S.; Rodríguez-Franco, M. I. Old phenothiazine and dibenzothiadiazepine derivatives for tomorrow's neuroprotective therapies against neurodegenerative diseases Eur. J. Med. Chem. 2010, 45, 6152-6158
53. Arce, M. P.; Rodríguez-Franco, M. I.; González-Muñoz, G. C.; Pérez, C.; López, B.; Villarroya, M.; López, M. G.; García, A. G.; Conde, S. Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease J. Med. Chem. 2009, 52, 7249-7257
54. Rodríguez-Franco, M. I.; Fernández-Bachiller, M. I.; Pérez, C.; Hernández-Ledesma, B.; Bartolomé, B. Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties J. Med. Chem. 2006, 49, 459-462 (Pubitemid 43157478)
55. Pietta, P. G. Flavonoids as antioxidants J. Nat. Prod. 2000, 63, 1035-1042
56. Saxena, A.; Fedorko, J. M.; Vinayaka, C. R.; Medhekar, R.; Radić, Z.; Taylor, P.; Lockridge, O.; Doctor, B. P. Aromatic amino-acid residues at the active and peripheral anionic sites control the binding of E2020 (Aricept) to cholinesterases Eur. J. Biochem. 2003, 270, 4447-4458 (Pubitemid 37452521)
57. Carlier, P. R.; Chow, E. S.-H.; Han, Y.; Liu, J.; El Yazal, J.; Pang, Y.-P. Heterodimeric tacrine-based acetylcholinesterase inhibitors: investigating ligand-peripheral site interactions J. Med. Chem. 1999, 42, 4225-4231 (Pubitemid 29483039)
58. Wiley, P. F. Chromones in the Mannich reaction J. Am. Chem. Soc. 1952, 74, 4326-4329
59. Kostanecki, St. v.; de Ruijter de Wildt, J. C. Ueber das 1,3-dioxychromon Chem. Ber. 1902, 35, 861-865
60. Badcock, G. G.; Dean, F. M.; Robertson, A.; Whalley, W. B. The chemistry of fungi. Part X. The synthesis of 4-hydroxy-3-acetylcoumarins J. Chem. Soc. 1950, 903-908
61. Stoermer, M. J.; Fairlie, D. P. A selective and versatile synthesis of substituted chromones via addition of phenols to dimethyl acetylenedicarboxylate Aust. J. Chem. 1995, 48, 677-686
62. Ellman, G. L.; Courteney, K. D.; Andres, V., Jr.; Feather-Stone, R. M. A new and rapid colorimetric determination of acetylcholinesterase activity Biochem. Pharmacol. 1961, 7, 88-95
63. Cyglerm, M.; Scharg, J. D.; Sussman, J. L.; Harel, M.; Silman, I.; Gentry, M. K.; Doctor, B. P. Relationship between sequence conservation and three-dimensional structure in a large family of esterases, lipases, and related proteins Protein Sci. 1993, 2, 366-382 (Pubitemid 23071285)
64. Bhatt, M. V.; Kulkarni, S. U. Cleavage of ethers Synthesis 1983, 249-282
65. McOmie, J. F. W.; Watts, M. L.; West, D. E. Demethylation of aryl methyl ethers by boron tribromide Tetrahedron 1968, 24, 2289-2292
66. Ou, B.; Hampsch-Woodill, M.; Prior, R. L. Development and validation of an improved oxygen radical absorbance capacity assay using fluorescein as the fluorescent probe J. Agric. Food Chem. 2001, 49, 4619-4626 (Pubitemid 32988695)
67. Dávalos, A.; Gómez-Cordobés, C.; Bartolomé, B. Extending applicability of the oxygen radical absorbance capacity (ORAC-fluorescein) assay J. Agric. Food Chem. 2004, 52, 48-54
68. Sofic, E.; Rimpapa., Z.; Kundurovic, Z.; Sapcanin, A.; Tahirovic, I.; Rustembegoric, A.; Cao, G. Antioxidant capacity of the neurohormone melatonin J. Neural Transm. 2005, 112, 349-358 (Pubitemid 40868049)
69. Martín, I.; Aspée, A.; Torres, P.; Lissi, E.; López-Alarcón, C. Influence of the target molecule on the oxygen radical absorbance capacity index: a comparison between alizarin red- and fluorescein-based methodologies J. Med. Food 2009, 12, 1386-1392
70. Di, L.; Kerns, E. H.; Fan, K.; McConnell, O. J.; Carter, G. T. High throughput artificial membrane permeability assay for blood-brain barrier Eur. J. Med. Chem. 2003, 38, 223-232 (Pubitemid 36349665)
71. Viayna, E.; Gómez, T.; Galdeano, C.; Ramírez, L.; Ratia, M.; Badia, A.; Clos, M. V.; Verdaguer, E.; Junyent, F.; Camins, A.; Pallàs, M.; Bartolini, M.; Mancini, F.; Andrisano, V.; Arce, M. P.; Rodríguez-Franco, M. I.; Bidon-Chanal, A.; Luque, F. J.; Camps, P.; Muñoz-Torrero, D. Novel huprine derivatives with inhibitory activity toward β-amyloid aggregation and formation as disease-modifying anti-Alzheimer drug candidates ChemMedChem 2010, 5, 1855-1870
72. Camps, P.; Formosa, X.; Galdeano, C.; Muñoz-Torrero, D.; Ramírez, L.; Gómez, E.; Isambert, N.; Lavilla, R.; Badia, A.; Clos, M. V.; Bartolini, M.; Mancini, F.; Andrisano, V.; Arce, M. P.; Rodríguez-Franco, M. I.; Huertas, O.; Dafni, To.; Luque, F. J. Pyrano[ 3, 2 -c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and β-amyloid-directed anti-Alzheimer compounds J. Med. Chem. 2009, 52, 5365-5379
73. Marco-Contelles, J.; León, R.; de los Ríos, C.; Samadi, A.; Bartolini, M.; Andrisano, V.; Huertas, O.; Barril, X.; Luque, F. J.; Rodríguez-Franco, M. I.; López, B.; López, M. G.; García, A. G.; Carreiras, M. C.; Villarroya, M. Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease J. Med. Chem. 2009, 52, 2724-2732
74. Reviriego, F.; Rodríguez-Franco, M. I.; Navarro, P.; García-España, E.; Liu-González, M.; Verdejo, B.; Domènech, A. The sodium salt of diethyl 1 H -pyrazole-3,5-dicarboxylate as an efficient amphiphilic receptor for dopamine and amphetamines. Crystal structure and solution studies J. Am. Chem. Soc. 2006, 128, 16458-16459 (Pubitemid 46032698)
75. Pavón, F. J.; Hernández-Folgado, L.; Bilbao, A.; Cippitelli, A.; Jagerovic, N.; Abellán, G.; Rodríguez-Franco, M. I.; Serrano, A.; Macías, M.; Navarro, M.; Goya, P.; Rodríguez de Fonseca, F. Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4- triazole-LH 21 Neuropharmacology 2006, 51, 358-366
76. Kennedy, M. E.; Wang, W.; Song, L.; Lee, J.; Zhang, L.; Wong, G.; Wang, L.; Parker, E. Measuring human β-secretase (BACE1) activity using homogeneous time-resolved fluorescence Anal. Biochem. 2003, 319, 49-55 (Pubitemid 36805626)
77. Mancini, F.; De Simone, A.; Andrisano, V. Beta-secretase as a target for Alzheimer's disease drug discovery: an overview of in vitro methods for characterization of inhibitors Anal. Bioanal. Chem. 2011, 400, 1979-1996
78. Marcinkeviciene, L.; Luo, Y.; Graciani, N. R.; Combs, A. P.; Copeland, R. A. Mechanism of inhibition of beta-site amyloid precursor protein-cleaving enzyme (BACE) by statine-based peptide J. Biol. Chem. 2001, 276, 23790-23794
79. Hong, L.; Koelsch, G.; Lin, X.; Wu, S.; Terzyan, S.; Ghosh, A. K.; Zhang, X. C.; Tang, J. Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor Science 2000, 290, 150-153
80. Ermolieff, J.; Loy, J. A.; Koelsch, G.; Tang, J. Proteolytic activation of recombinant pro-memapsin 2 (pro-β-secretase) studied with new fluorogenic substrates Biochemistry 2000, 39, 12450-12456
81. Cheng, Y. C.; Prusoff, W. H. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50% inhibition (IC50) of an enzymatic reaction Biochem. Pharmacol. 1973, 22 (23) 3099-3108
82. Willem, M.; Garratt, A. N.; Novak, B.; Citron, M.; Kaufmann, S.; Rittger, A.; DeStrooper, B.; Saftig, P.; Birchmeier, C.; Haass, C. Control of peripheral nerve myelination by the beta-secretase BACE1 Science 2006, 314, 664-666 (Pubitemid 44646394)
83. Savonenko, A. V.; Melnikova, T.; Laird, F. M.; Stewart, K. A.; Price, D. L.; Wong, P. C. Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice Proc. Natl. Acad. Sci. U S A 2008, 105, 5585-5590 (Pubitemid 351753906)
84. Fu, H.; Li, W.; Luo, J.; Lee, N. T. K.; Li, M.; Tsim, K. W. K.; Pang, Y.; Youdim, M. B. H.; Han, Y. Promising anti-Alzheimer's dimer bis(7)-tacrine reduces β-amyloid generation by directly inhibiting BACE-1 activity Biochem. Biophys. Res. Commun. 2008, 366, 631-636